7-氨基-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-恶嗪-3(4H)-酮 | 575473-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 7-氨基-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-恶嗪-3(4H)-酮
• 英文名称: 7-amino-2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one
• 英文别名: 7-amino-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
• CAS: 575473-97-1
• 化学式: C₉H₁₁N₃O₂
• mdl: MFCD11110239
• 分子量: 193.205
• InChiKey: PMJGYEUKMGIHEP-UHFFFAOYSA-N

物化性质

• 密度：
  1.256

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  77.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-噻吩磺酰氯 、 7-氨基-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-恶嗪-3(4H)-酮 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-(2,2-dimethyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)thiophene-2-sulfonamide
  参考文献：
  名称：

  Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer

  摘要：

  Prostate cancer is a commonly diagnosed cancer and a leading cause of cancer-related deaths. The bromodomain and extra terminal domain (BET) family proteins have emerged as potential therapeutic targets for the treatment of castration resistant prostate cancer. A series of 2,2-dimethy1-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives were designed and synthesized as selective bromodomain containing protein 4 (BRD4) inhibitors. The compounds potently inhibit BRD4(1) with nanomolar IC50 values and exhibit high selectivity over most non-BET subfamily members. One of the representative compounds 36 (Y08060) effectively suppresses cell growth, colony formation, and expression of androgen receptor (AR), AR regulated genes, and MYC in prostate cancer cell lines. In in vivo studies, 36 demonstrates a good PK profile with high oral bioavailability (61.54%) and is a promising lead compound for further prostate cancer drug development.

  DOI：

  10.1021/acsmedchemlett.8b00003
• 作为产物：
  描述：

  2-氨基-3-羟基吡啶 在 硫酸 、 palladium on carbon 、 氢气 、 硝酸 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 7-氨基-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-恶嗪-3(4H)-酮
  参考文献：
  名称：

  Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer

  摘要：

  Prostate cancer is a commonly diagnosed cancer and a leading cause of cancer-related deaths. The bromodomain and extra terminal domain (BET) family proteins have emerged as potential therapeutic targets for the treatment of castration resistant prostate cancer. A series of 2,2-dimethy1-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives were designed and synthesized as selective bromodomain containing protein 4 (BRD4) inhibitors. The compounds potently inhibit BRD4(1) with nanomolar IC50 values and exhibit high selectivity over most non-BET subfamily members. One of the representative compounds 36 (Y08060) effectively suppresses cell growth, colony formation, and expression of androgen receptor (AR), AR regulated genes, and MYC in prostate cancer cell lines. In in vivo studies, 36 demonstrates a good PK profile with high oral bioavailability (61.54%) and is a promising lead compound for further prostate cancer drug development.

  DOI：

  10.1021/acsmedchemlett.8b00003

文献信息

• 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
  申请人：Singh Rajinder

  公开号：US20090171085A1

  公开（公告）日：2009-07-02

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了一种2,4-嘧啶二胺化合物，其抑制IgE和/或IgG受体信号级联，从而导致化学介质的释放，中间体和合成化合物的方法以及在各种情况下使用化合物的方法，包括在通过去颗粒化和其他由IgE和/或IgG受体信号级联的激活引起的化学介质释放所表征，引起或与之相关的疾病的治疗和预防。
• US7803939B2
  申请人：——

  公开号：US7803939B2

  公开（公告）日：2010-09-28
• Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer
  作者：Qiuping Xiang、Yan Zhang、Jiaguo Li、Xiaoqian Xue、Chao Wang、Ming Song、Cheng Zhang、Rui Wang、Chenchang Li、Chun Wu、Yulai Zhou、Xiaohong Yang、Guohui Li、Ke Ding、Yong Xu

  DOI：10.1021/acsmedchemlett.8b00003

  日期：2018.3.8

  Prostate cancer is a commonly diagnosed cancer and a leading cause of cancer-related deaths. The bromodomain and extra terminal domain (BET) family proteins have emerged as potential therapeutic targets for the treatment of castration resistant prostate cancer. A series of 2,2-dimethy1-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives were designed and synthesized as selective bromodomain containing protein 4 (BRD4) inhibitors. The compounds potently inhibit BRD4(1) with nanomolar IC50 values and exhibit high selectivity over most non-BET subfamily members. One of the representative compounds 36 (Y08060) effectively suppresses cell growth, colony formation, and expression of androgen receptor (AR), AR regulated genes, and MYC in prostate cancer cell lines. In in vivo studies, 36 demonstrates a good PK profile with high oral bioavailability (61.54%) and is a promising lead compound for further prostate cancer drug development.